



ABN 30 116 800 269

Level 7, 1008 Hay Street
Perth WA 6000
PO Box 7209
Cloisters Square WA 6850

Ph +61 8 9389 2000
Fax +61 8 9389 2099
info@erinresources.com

Erin Resources Ltd (ASX: ERI) soon to be renamed MGC Pharmaceuticals Ltd

11 November 2015

Investor Report by the Next Bio Tech

Erin Resources Ltd (ASX: ERI), soon to be renamed MGC Pharmaceuticals Ltd, is pleased to announce the publication of an article on the Company's activities and investment opportunity for current and potential ERI shareholders by Next Bio Tech.

This report is an initiation note by Next Bio Tech, which can be read by clicking [here](#) and is also available on the company website <http://mgcpharma.com.au/#MediaNews>

-Ends-

For further information please contact:

Media Enquiries

Asher Moses
Director
Media and Capital Partners
+61 438 008 616
Asher.moses@mcpartners.com.au

Erin Resources Limited

Brett Mitchell
Executive Chairman
+61 8 9389 2000
info@erinresources.com.au

About MGC Pharmaceuticals

MGC Pharmaceuticals (MGC) is EU based specialist medical and cosmetic cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabinoid resin extract ("CBD") to the growing European cosmetics and medical markets.

About Erin Resources – Acquisition of MGC Pharmaceuticals

Erin Resources executed a binding heads of agreement with the option to acquire 100% of the issued capital of MGC Pharmaceuticals, as announced on 18 May 2015. The Option has been exercised and the Company has called a shareholder meeting to approve the acquisition on 16 November 2015, including the Company's name change to MGC Pharmaceuticals Ltd.